drugset
drugset / Trial / NCT06600581

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

NCT06600581 ↗

Phase 2 Active not recruiting 55 enrolled Immunis, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness

Timeline

Start
2024-12-19
Primary completion
2026-07-15
Completion
2026-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject IMM01-STEM Unknown 0.5 mg Intramuscular
Subject IMM01-STEM Unknown 1 mg Intramuscular
Subject IMM01-STEM Unknown 2 mg Intramuscular

Indications

No indication recorded.